股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 植華集團投資控股有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01842 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...

Core Viewpoint - The company reported a revenue of HKD 147 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 2.6% and a net loss of HKD 8.466 million, which represents a 47.1% increase in losses compared to the previous year [1] Financial Performance - Revenue for the reporting period was HKD 147 million, down from HKD 150.8 million in the first half of 2024 [1] - The net loss increased to HKD 8.466 million, compared to a loss of HKD 5.76 million in the same period last year [1] - Basic loss per share was HKD 0.71 cents [1] Factors Contributing to Performance - The increase in net loss was primarily due to an unrealized fair value loss on listed securities amounting to approximately HKD 3.3 million, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses rose by approximately HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development plans [1] - Recent developments in U.S. tariffs have negatively impacted these initiatives, leading to limited short-term visibility on expected benefits [1]

Core Viewpoint - Zhihua Group (01842) reported a decline in revenue and an increase in net loss for the six months ending June 30, 2025, indicating challenges in its financial performance and market conditions [1] Financial Performance - Revenue for the period was HKD 147 million, a decrease of 2.6% year-on-year [1] - The net loss expanded to HKD 8.466 million, an increase of 47.1% compared to the previous year [1] - Basic loss per share was HKD 0.071 [1] Contributing Factors - The increase in net loss was primarily due to: - Unrealized fair value losses on listed securities amounting to approximately HKD 3.3 million, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses increased by approximately HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development plans [1] Market Conditions - Recent developments in U.S. tariffs have negatively impacted the company's initiatives, leading to limited short-term visibility on expected benefits [1] - Revenue decreased from HKD 150.8 million in the first half of 2024 to HKD 147 million during the reporting period [1]

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 146,959,000, a decrease of 2% compared to HKD 150,847,000 for the same period in 2024[2] - The company reported a loss of HKD 8,466,000 for the current period, compared to a loss of HKD 5,754,000 in the previous year, indicating a worsening performance[2] - Gross profit for the period was HKD 23,054,000, up from HKD 21,865,000, reflecting a 5.4% increase year-over-year[4] - The company reported a net loss before tax of HKD 8,822,000, compared to HKD 6,271,000 in the previous year, indicating a worsening financial position[4] - Other comprehensive loss for the period totaled HKD 9,634,000, compared to HKD 6,063,000 in the previous year, representing an increase of 59.5%[4] - The basic loss per share was HKD 0.71, compared to HKD 0.48 in the same period last year, reflecting a 47.9% increase in losses per share[4] Assets and Liabilities - Total assets decreased to HKD 224,694,000 from HKD 260,599,000, representing a decline of approximately 13.8%[2] - Current liabilities were HKD 101,396,000, down from HKD 128,720,000, showing a reduction of about 21.2%[2] - The net asset value of the company was HKD 121,531,000, compared to HKD 131,165,000, indicating a decrease of approximately 7.3%[2] - The debt-to-asset ratio stood at 37.4%, slightly improved from 39.0% in the previous year[2] - The company’s total liabilities decreased from HKD 139,434 million to HKD 103,163 million, a reduction of about 26%[5] - The company’s non-current liabilities were recorded at HKD 103,163,000, down from HKD 129,434,000, showing a reduction of about 20.3%[6] Cash Flow and Financing - Cash and cash equivalents increased to HKD 61,573 million from HKD 54,056 million, showing a growth of around 14%[5] - Interest income from bank deposits amounted to HKD 414 million for the six months ended June 30, 2025, compared to HKD 917 million for the same period in 2024, representing a decrease of 54.8%[21] - Net financing costs were HKD 1,012 million for the six months ended June 30, 2025, compared to HKD 717 million for the same period in 2024, indicating an increase of 40.9%[21] - The annual interest rate for bank borrowings ranged from 1.5% to 5.3% as of June 30, 2025, compared to 3.8% to 5.7% as of December 31, 2024[42] Operational Focus - The company is focused on expanding its product lines in the medical-related products sector, which is expected to drive future revenue growth[7] - The group identified its main operational focus on the private label product segment, which includes design, development, procurement, manufacturing, and sales of various products[16] - The group’s operating activities are primarily concentrated on the private label product segment, as reviewed by key operating decision-makers[16] Employee and Corporate Governance - The company employed approximately 396 employees as of June 30, 2025, a decrease from approximately 412 employees on June 30, 2024[63] - The company has adhered to all corporate governance codes during the reporting period[72] - The audit committee has been established in accordance with listing rules and consists of three independent non-executive directors[79] Future Outlook - The company anticipates a slowdown in global GDP growth in the second half of 2025, with various competitive pressures expected[71] - The group has not disclosed specific future outlook or guidance in the provided content[16] Shareholder Information - The company reported no interim dividend for the six months ending June 30, 2025, consistent with the previous year[44] - There are no unexercised share options as of June 30, 2025, and no share options have been granted, exercised, cancelled, or lapsed during the reporting period[76] - The company and its subsidiaries did not buy, sell, or redeem any listed securities during the reporting period[77]

格隆汇8月12日丨植华集团(01842.HK)公布，公司将于2025年8月22日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Grown Up Group Investment Holdings Limited 植 華 集 團 投 資 控 股 有 限 公 司 董事會會議日期 植華集團投資控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本 公司謹訂於二零二五年八月二十二日（ 星期五 ）舉行董事會會議，藉以考慮及批准 （ 其中包括 ）本公司及其附屬公司截至二零二五年六月三十日止六個月之未經審核 綜合中期業績及其刊發，以及考慮派發中期股息（ 如有 ）。 承董事會命 植華集團投資控股有限公司 主席兼執行董事 （於開曼群島註冊成立的有限公司） （股份代號：1842） 香港，二零二五年八月十二日 於本公告日期，執行董事為Thomas Berg先生、薛雅麗女士及Jan Ankersen先生； 以及獨立非執行董事為曾慶煊先生、黃繼興先生及陳霆畧先生。 Thom ...

截至月份: 2025年7月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致：香港交易及結算所有限公司 公司名稱: 植華集團投資控股有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01842 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000 ...

Core Viewpoint - The company, Zhihua Group (01842.HK), anticipates a significant increase in net losses for the first half of 2025, projecting a rise of approximately 40% to 50% compared to the net loss of about HKD 5.8 million for the first half of 2024 [1] Summary by Relevant Categories Financial Performance - The expected increase in net losses for the first half of 2025 is primarily attributed to a slight decline in revenue due to ongoing tariff pressures from the United States [1] - The company is set to recognize an unrealized loss of approximately HKD 3.3 million from listed securities investments in the first half of 2025, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses are projected to rise by about HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development initiatives [1]

Group 1 - The company, Zhihua Group (01842.HK), reported a net loss of approximately HKD 5.8 million for the six months ending June 30, 2024, and anticipates a net loss increase of about 40% to 50% in the first half of 2025 [1] - The expected increase in net loss for the first half of 2025 is primarily due to a slight decline in revenue, mainly attributed to ongoing tariff-related pressures from the United States [1] - The company confirmed an unrealized loss of approximately HKD 3.3 million on listed securities investments for the first half of 2025, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses are expected to rise by approximately HKD 1.9 million, mainly due to the company's efforts to strengthen its diversified supply chain network and advance business development initiatives [1]

植华集团(01842)发布公告，与截至2024年6月30日止6个月约580万港元的亏损净额相比，集团可能于 2025年上半年取得亏损净额增加约40%至50%。预期2025年上半年的亏损净额增加乃主要由于(i)2025年 上半年的收益轻微下降，乃主要由于美国持续的关税相关压力;(ii)确认2025年上半年上市证券投资公平 值未变现亏损约330万港元，而2024年上半年则取得亏损220万港元;及(iii)行政开支增加约190万港元， 乃主要由于集团加强多元化供应链网络及推进业务发展措施所致。 ...